Pharmacotherapeutic options for atypical meningiomas
暂无分享,去创建一个
[1] Simona Lionti,et al. High p‐mTOR expression is associated with recurrence and shorter disease‐free survival in atypical meningiomas , 2018, Neuropathology : official journal of the Japanese Society of Neuropathology.
[2] I. Codreanu,et al. Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs , 2019, Expert opinion on biological therapy.
[3] N. Geifman,et al. New drug candidates for treatment of atypical meningiomas: An integrated approach using gene expression signatures for drug repurposing , 2018, PloS one.
[4] Mark W. Youngblood,et al. Integrated genomic analyses of de novo pathways underlying atypical meningiomas , 2017, Nature Communications.
[5] Sur Sharma,et al. Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination , 2017, Expert opinion on biological therapy.
[6] D. Shrieve,et al. Adjuvant radiotherapy for atypical meningiomas. , 2016, Journal of neurosurgery.
[7] K. Wei,et al. Long Term Surgical Outcome and Prognostic Factors of Atypical and Malignant Meningiomas , 2016, Scientific Reports.
[8] Y. Shoshan,et al. Review of controversies in management of non-benign meningioma , 2016, Journal of Clinical Neuroscience.
[9] M. Levivier,et al. Recent advances in the management of atypical meningiomas. , 2016, Neuro-Chirurgie.
[10] G. Sethi,et al. The potential role of boswellic acids in cancer prevention and treatment. , 2016, Cancer letters.
[11] S. Johansen,et al. Differentially Expressed MicroRNAs in Meningiomas Grades I and II Suggest Shared Biomarkers with Malignant Tumors , 2016, Cancers.
[12] S. Elbabaa,et al. Innovative Therapeutic Strategies in the Treatment of Meningioma. , 2015, Anticancer research.
[13] K. Stelzer,et al. Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] K. Choe,et al. Atypical Meningiomas: Recurrence, Reoperation, and Radiotherapy. , 2015, World neurosurgery.
[15] M. Chicoine,et al. An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas. , 2015, Neurosurgical focus.
[16] Katrina H. Smith,et al. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma , 2015, Neurology.
[17] P. Wen,et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. , 2015, Neuro-oncology.
[18] P. Wen,et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review , 2014 .
[19] A. Rademaker,et al. A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas , 2014, Journal of Neuro-Oncology.
[20] G. Zada,et al. Recent developments in chemotherapy for meningiomas: a review. , 2013, Neurosurgical focus.
[21] S. Ćurić,et al. Curcumin acts anti-proliferative and pro-apoptotic in human meningiomas , 2013, Journal of Neuro-Oncology.
[22] S. Spiegl-Kreinecker,et al. Trabectedin has promising antineoplastic activity in high‐grade meningioma , 2012, Cancer.
[23] WJ Sherman,et al. Chemotherapy: what is its role in meningioma? , 2012, Expert review of neurotherapeutics.
[24] R. McLendon,et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series , 2012, Journal of Neuro-Oncology.
[25] M. Chamberlain. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma , 2012, Journal of Neuro-Oncology.
[26] J. Barnholtz-Sloan,et al. Medical treatment of recurrent meningiomas , 2011, Expert review of neurotherapeutics.
[27] C. Schulz,et al. Treatment of unresectable skull base meningiomas with somatostatin analogs. , 2011, Neurosurgical focus.
[28] M. Chamberlain,et al. Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series , 2011, Journal of Neuro-Oncology.
[29] Joseph Wiemels,et al. Epidemiology and etiology of meningioma , 2010, Journal of Neuro-Oncology.
[30] F. Thorsen,et al. Gamma Knife Surgery of Meningiomas Involving the Cavernous Sinus: Long‐term Follow‐up of 100 Patients , 2010, Neurosurgery.
[31] Susan M. Chang,et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). , 2009, Neuro-oncology.
[32] M. J. van den Bent,et al. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma , 2009, British Journal of Cancer.
[33] Susan M. Chang,et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma , 2009, Journal of Neuro-Oncology.
[34] M. Chamberlain,et al. Interferon‐α for recurrent World Health Organization grade 1 intracranial meningiomas , 2008, Cancer.
[35] M. Chamberlain,et al. Recurrent meningioma , 2007, Neurology.
[36] Y. Chung,et al. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[37] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[38] Thomas C. Chen,et al. Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas. , 2007, Journal of neurosurgery.
[39] C. Russell,et al. Long-Term Administration of Mifepristone (RU486): Clinical Tolerance During Extended Treatment of Meningioma , 2006, Cancer investigation.
[40] Mahlon D. Johnson,et al. Mitogenic Signal Transduction Pathways in Meningiomas: Novel Targets for Meningioma Chemotherapy? , 2005, Journal of neuropathology and experimental neurology.
[41] V. Puduvalli,et al. Induction of apoptosis in primary meningioma cultures by fenretinide. , 2005, Cancer research.
[42] J. Crowley,et al. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group study , 2005, Journal of Neuro-Oncology.
[43] A. Órfão,et al. Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (FISH): is there a relationship between histopathologically benign and atypical/anaplastic lesions? , 2004, The Journal of molecular diagnostics : JMD.
[44] S. Groshen,et al. Temozolomide for treatment-resistant recurrent meningioma , 2004, Neurology.
[45] R. Ojemann,et al. Management of Atypical and Malignant Meningiomas: Role of High-dose, 3D-conformal Radiation Therapy , 2000, Journal of Neuro-Oncology.
[46] W. Mason,et al. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. , 2002, Journal of neurosurgery.
[47] J. Harwalkar,et al. Acetyl-11-keto-beta-boswellic acid (AKBA) is cytotoxic for meningioma cells and inhibits phosphorylation of the extracellular-signal regulated kinase 1 and 2. , 1999, Advances in experimental medicine and biology.
[48] J. A. Scarlett,et al. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. , 2001, Journal of neurosurgery.
[49] M. Westphal,et al. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. , 2000, Neurosurgery.
[50] R. Radinsky,et al. Growth hormone receptor expression and function in meningiomas: effect of a specific receptor antagonist. , 1999, Journal of neurosurgery.
[51] M. Weller,et al. © 1999 Cancer Research Campaign Article no. bjoc.1998.0419 Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity , 2022 .
[52] J. Bruner,et al. The Treatment of Recurrent Unresectable and Malignant Meningiomas with Interferon Alpha-2B. , 1997, Neurosurgery.
[53] R. Fahlbusch,et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. , 1997, Journal of neurosurgery.
[54] R. Fahlbusch,et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. , 1997, Journal of neurosurgery.
[55] J. Bruner,et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. , 1997, Neurosurgery.
[56] J. Foekens,et al. Progesterone, oestradiol, somatostatin and epidermal growth factor receptors on human meningiomas and their CT characteristics. , 1991, European journal of cancer.
[57] R. Barnard,et al. The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.